Last reviewed · How we verify

Lumateperone (ITI-007) — Competitive Intelligence Brief

Lumateperone (ITI-007) (Lumateperone (ITI-007)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-dopamine antagonist. Area: Psychiatry.

phase 3 Serotonin-dopamine antagonist 5-HT2A receptor, D2 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Lumateperone (ITI-007) (Lumateperone (ITI-007)) — Intra-Cellular Therapies, Inc.. Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lumateperone (ITI-007) TARGET Lumateperone (ITI-007) Intra-Cellular Therapies, Inc. phase 3 Serotonin-dopamine antagonist 5-HT2A receptor, D2 receptor
Lumateperone low dose Lumateperone low dose Intra-Cellular Therapies, Inc. phase 3 Serotonin-dopamine antagonist 5-HT2A receptor, D2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-dopamine antagonist class)

  1. Intra-Cellular Therapies, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lumateperone (ITI-007) — Competitive Intelligence Brief. https://druglandscape.com/ci/lumateperone-iti-007. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: